DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (MDT) (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's ...

Medical tech company Medtronic has just landed FDA clearance on its Deep Brain Stimulation (DBS) Clinical Programmer and ActivaProgramming application. "This marks a new era of innovation from the ...

On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...

Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for BrainSense Adaptive deep brain stimulation (DBS)and BrainSense Electrode ...

Live On is a campaign that encourages patients to get to know more about neuromodulation options from Medtronic DBS. The campaign seeks to address one of the biggest challenges in Parkinson’s and ...

MINNEAPOLIS--(BUSINESS WIRE)-- In the largest, randomized, controlled study of deep brain stimulation (DBS) for Parkinson’s disease, Medtronic DBS Therapy was shown to improve motor function for up to ...

Medtronic plc’s Brainsense adaptive deep brain stimulation system has been shown to be tolerable, effective and safe for long-term use at home in people with Parkinson’s disease. A study published in ...

MINNEAPOLIS, Minnesota — The U.S. Food and Drug Administration approved a Medtronic deep brain stimulation treatment to treat obsessive compulsive disorder – the first deep brain stimulation treatment ...